Table 1 DR-TB background notifications and trial enrollments in select endTB, endTB-Q and TB-PRACTECAL study areas in 2019 and 2020, and percent change
From: TB research requires strong protections, innovation, and increased funding in response to COVID-19
DR-TB notifications or trial enrollments | DR-TB notifications or trial enrollments | ||||||
|---|---|---|---|---|---|---|---|
Quarter 1 (Jan–Mar) | Quarter 2 (Apr–Jun) | ||||||
Country | Setting | 2019 | 2020 | % change 2019–2020 | 2019 | 2020 | % change 2019–2020 |
Belarus | Background notification* | 253 | 232 | − 8.3% | 212 | 163 | − 23.1% |
TB-PRACTECAL† | 6 | 12 | + 100% | 5 | 8 | + 60% | |
Kazakhstan | Background notification‡ | 95 | 62 | − 34.7% | 93 | 45 | − 51.6% |
endTB AND endTB-Q | 18 | 6 | − 66.6% | 19 | 6 | − 68.4% | |
India | Background notification§ | 230 | 252 | + 9.57% | 217 | 142 | − 34.6% |
endTB AND endTB-Q¶ | NA | NA | NA | NA | NA | NA | |
Lesotho | Background notification** | 49 | 38 | − 22.4% | 38 | 21 | − 44.7% |
endTB AND endTB-Q | 6 | 1 | − 83.3% | 5 | 2 | − 60% | |